ALB and gastroesophageal junction adenocarcinoma: Thus, we conducted a clinical trial to evaluate the efficacy and safety of the combination of camrelizumab, albumin-bound paclitaxel and S-1 as first-line treatment for patients with advanced G/GEJ adenocarcinoma.